. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Apr 24;20(8):1248–1251. doi: 10.1016/j.bbmt.2014.04.024

Table 1. Summary results.

For each variable, outcome and subgroup of interest, the hazard ratio is given along with its associated 95% confidence interval and p value.

Population	Outcome	Variable	HR (95CI, p value)
Overall cohort	Overall Survival	LIC>5 mg/gdw LIC>7 mg/gdw SF > 1000 ng/ml SF > 2500 ng/ml	1.0 (0.6–1.5), p=1.0 1.4 (0.9–2.3), p=0.2 1.7 (1.0–2.7), p=0.036 1.3 (0.8–2.0), p=0.3
Overall cohort	Non-relapse mortality	LIC>5 mg/gdw LIC>7 mg/gdw SF > 1000 ng/ml SF > 2500 ng/ml	1.0 (0.6–1.7), p=0.9 1.7 (0.9–3.3), p=0.09 1.6 (0.9–2.8), p=0.14 1.4 (0.8–2.3), p=0.3
MAC cohort	Overall Survival	LIC>7 mg/gdw SF > 1000 ng/ml	1.3 (0.4–4.4), p=0.6 1.5 (0.6–3.5), p=0.4
MAC cohort	Non-relapse mortality	LIC>7 mg/gdw SF > 1000 ng/ml	Not evaluable^b
RIC cohort^a	Overall Survival	LIC>7 mg/gdw SF > 1000 ng/ml	1.5 (0.8–2.7), p=0.2 1.5 (0.8–2.8), p=0.2
RIC cohort^a	Non-relapse mortality	LIC>7 mg/gdw SF > 1000 ng/ml	2.2 (1.1–4.6), p=0.026^a 1.5 (0.7–3.3), p=0.3
Acute leukemia + MDS	Overall Survival	LIC>7 mg/gdw SF > 1000 ng/ml	1.2 (0.7–2.3), p=0.6 1.5 (0.7–3.1), p=0.3
Acute leukemia + MDS	Non-relapse mortality	LIC>7 mg/gdw SF > 1000 ng/ml	1.5 (0.7–3.0), p=0.3 1.1 (0.6–2.2), p=0.7

HR denotes hazard ratio; 95CI, 95% confidence interval; LIC, liver iron content; SF, serum ferritin; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; MDS, myelodysplastic syndromes.

See text for comment

Due to the small number of events in this subgroup.